Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer

被引:17
作者
Zhang, Wei [1 ]
Wang, Liying [1 ]
Xin, Zhongqiu [1 ]
机构
[1] Gen Hosp, Daqing Oil Field, Dept Ultrasound, Zhongkang St 9, Daqing 163001, Peoples R China
关键词
cancer antigen; contrast enhanced ultrasound; diagnosis; malignant epithelial cancer; ovarian serous carcinoma; TUMORS; CA-125;
D O I
10.1097/MD.0000000000010358
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ovarian serous carcinoma (OSC) is semimalignant ovarian tumors that localized in the ovary at the initial presentation, and can be surgically resected in an excellent prognosis. In contrast, surgical treatment plus adjuvant chemotherapy for ovarian malignant epithelial cancer (OMEC) is the standard treatment stratagem that is painful with poor prognosis and cost quite expensively. Thus, the accurate preoperative differentiation of OSC from OMEC is important for determining the treatment methods and decreasing the cost for individual patients. This study aims to determine whether contrast enhanced ultrasound (CEUS) together with CA19-9/CA125 can improve the ability to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer. The positive rate of cancer antigen (CA) 199 and CA125 in ovarian malignant epithelial tumors was 68% and 94%, respectively, which was a higher incidence than in the serous carcinoma. The mean serum CA19-9 and CA125 concentration was significantly higher in the patients with ovarian malignant epithelial tumors (CA19-9, 514.0 +/- 104.8 U/mL; CA125, 440.0 +/- 154.8 U/mL) than that in the patients with ovarian serous carcinoma (CA19-9, 58.0 +/- 14.3 U/mL; CA125, 63.0 +/- 25.8 U/mL). The time to peak in ovarian serous carcinoma was significantly longer than in ovarian malignant epithelial tumors. However, the peak intensity, area under the curve, and washout time in ovarian serous carcinoma were significantly lower than in ovarian malignant epithelial tumors. The addition of CA19-9/CA125 increased the sensitivities from 79% CEUS only to 85% for CEUS plus CA19-9/CA125 data, and increased the specificities from 65% CEUS only to 91% for CEUS plus the CA19-9/CA125 information. Thus, the addition of the serum CA19-9/CA125 levels to parametric CEUS data was of significant diagnostic value for differentiating OSC from OMEC.
引用
收藏
页数:4
相关论文
共 15 条
  • [1] Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
    Bowtell, David D.
    Boehm, Steffen
    Ahmed, Ahmed A.
    Aspuria, Paul-Joseph
    Bast, Robert C., Jr.
    Beral, Valerie
    Berek, Jonathan S.
    Birrer, Michael J.
    Blagden, Sarah
    Bookman, Michael A.
    Brenton, James D.
    Chiappinelli, Katherine B.
    Martins, Filipe Correia
    Coukos, George
    Drapkin, Ronny
    Edmondson, Richard
    Fotopoulou, Christina
    Gabra, Hani
    Galon, Jerome
    Gourley, Charlie
    Heong, Valerie
    Huntsman, David G.
    Iwanicki, Marcin
    Karlan, Beth Y.
    Kaye, Allyson
    Lengyel, Ernst
    Levine, Douglas A.
    Lu, Karen H.
    McNeish, Iain A.
    Menon, Usha
    Narod, Steven A.
    Nelson, Brad H.
    Nephew, Kenneth P.
    Pharoah, Paul
    Powell, Daniel J., Jr.
    Ramos, Pilar
    Romero, Iris L.
    Scott, Clare L.
    Sood, Anil K.
    Stronach, Euan A.
    Balkwill, Frances R.
    [J]. NATURE REVIEWS CANCER, 2015, 15 (11) : 668 - 679
  • [2] Cho HY, 2014, MED SCI MONITOR, V20, P1334, DOI 10.12659/MSM.890954
  • [3] High CA-125 and CA19-9 levels in spontaneous ruptured ovarian endometriomas
    Dai, Xinyue
    Jin, Chu
    Hu, Yan
    Zhang, Qian
    Yan, Xiaojian
    Zhu, Fangfang
    Lin, Feng
    [J]. CLINICA CHIMICA ACTA, 2015, 450 : 362 - 365
  • [4] Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy
    Della Pepa, Chiara
    Tonini, Giuseppe
    Santini, Daniele
    Losito, Simona
    Pisano, Carmela
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Gargiulo, Piera
    Pignata, Sandro
    [J]. CANCER TREATMENT REVIEWS, 2015, 41 (02) : 136 - 143
  • [5] Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors
    Engelen, MJA
    de Bruijn, HWA
    Hollema, H
    ten Koor, KA
    Willemse, PHB
    Aalders, JG
    van der Zee, AGJ
    [J]. GYNECOLOGIC ONCOLOGY, 2000, 78 (01) : 16 - 20
  • [6] Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A metaanalysis
    Guo, Junhong
    Yu, Jiangtao
    Song, Xiaojie
    Mi, Haixia
    [J]. OPEN MEDICINE, 2017, 12 (01): : 131 - 137
  • [7] Usefulness of CA19-9 versus CA125 for the diagnosis of endometriosis
    Harada, T
    Kubota, T
    Aso, T
    [J]. FERTILITY AND STERILITY, 2002, 78 (04) : 733 - 739
  • [8] Low-grade serous ovarian cancer: A review
    Kaldawy, Anis
    Segev, Yakir
    Lavie, Ofer
    Auslender, Ron
    Sopik, Victoria
    Narod, Steven A.
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 143 (02) : 433 - 438
  • [9] Parametric Mapping of Contrasted Ovarian Transvaginal Sonography
    Korhonen, Katrina
    Moore, Ryan
    Lyshchik, Andrej
    Fleischer, Arthur C.
    [J]. ULTRASOUND QUARTERLY, 2015, 31 (02) : 117 - 123
  • [10] Contrast-Enhanced Ultrasonography in Differential Diagnosis of Benign and Malignant Ovarian Tumors
    Qiao, Jing-Jing
    Yu, Jing
    Yu, Zhe
    Li, Na
    Song, Chen
    Li, Man
    [J]. PLOS ONE, 2015, 10 (03):